- Rapid, durable, and significant reduction in spleen volume, with 28% of JAKAVI-treated patients achieving ≥35% reduction at 48 weeks1
- 97% of JAKAVI-treated patients achieving a reduction at any time2
This site is intended for Healthcare Professionals outside the US
BAT=best available therapy; CHR=complete haematologic remission; COMFORT=Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment; ITT=intent to treat; JAK=Janus kinase; QoL=quality of life; STAT=signal transducer and activator of transcription.
References: